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Background: Association studies based on next-generation sequencing (NGS) technology have become popular,
and statistical association tests for NGS data have been developed rapidly. A flexible tool for simulating sequence
data in either unrelated case–control or family samples with different disease and quantitative trait models would
be useful for evaluating the statistical power for planning a study design and for comparing power among
statistical methods based on NGS data.
Results: We developed a simulation tool, SeqSIMLA, which can simulate sequence data with user-specified disease
and quantitative trait models. We implemented two disease models, in which the user can flexibly specify the
number of disease loci, effect sizes or population attributable risk, disease prevalence, and risk or protective loci. We
also implemented a quantitative trait model, in which the user can specify the number of quantitative trait loci
(QTL), proportions of variance explained by the QTL, and genetic models. We compiled recombination rates from
the HapMap project so that genomic structures similar to the real data can be simulated.
Conclusions: SeqSIMLA can efficiently simulate sequence data with disease or quantitative trait models specified
by the user. SeqSIMLA will be very useful for evaluating statistical properties for new study designs and new
statistical methods using NGS. SeqSIMLA can be downloaded for free at http://seqsimla.sourceforge.net.Background
Computer programs that can simulate genotypes with phe-
notypes based on user-specified disease or quantitative trait
models are essential in genetic studies. They can be used
to evaluate statistical power when planning a study design
based on the proposed sample size, the assumed genotypic
relative risks (GRR), and allele frequencies. They are also
useful for evaluating type I error rates for new statistical as-
sociation tests and power comparisons between the new
tests and other existing tests. Therefore, many simulation
programs have been developed, mostly aiming to generate
genome-wide association study (GWAS) data with dichot-
omous or quantitative traits [1-5].
Next-generation sequencing (NGS) has become a popu-
lar technique for identifying novel rare variants associated
with complex diseases [6]. Statistical association tests that
can account for rare variants have also been developed
rapidly [7-10]. These tests aim to identify multiple rare
causal variants in a group of variants selected by biological* Correspondence: rchung@nhri.org.tw
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distribution, and reproduction in any mediumfunctions, such as exons, genes, and pathways. A common
approach is to pool all the variants in the group to in-
crease the statistical power for associations. To evaluate
the statistical power for new tests, a simulation tool that
can simulate multiple rare casual variants based on se-
quence data is necessary. However, simulation programs
developed for GWAS may not be appropriate for evaluat-
ing statistical properties for NGS studies, because they
were designed to simulate common variants based on
GWAS panels (e.g., Illumina and Affymetrix) or HapMap
project data [11]. Thus, computer software that can simu-
late sequence data based on realistic models with pheno-
types becomes important.
To our knowledge, SimRare is the only existing public
software designed specifically to simulate sequence data
with phenotypes [12]. SimRare has three modules, includ-
ing a sequence generation module, a module for pheno-
type generation based on genotypes, and a module for
evaluating association methods. The forward-time simula-
tion algorithm [5,13] is used in SimRare to generate vari-
ant data. SimRare focuses on generating unrelated
samples and on evaluating association methods developedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sociation studies using NGS are conducted [14-17], soft-
ware that can generate sequence data in families will be
very useful for evaluating the properties of family-based
NGS analysis.
We developed the Sequence and phenotype Simulator,
SeqSIMLA, which can simulate sequence data in unre-
lated case–control or family samples with user-specified
disease or quantitative trait models. SeqSIMLA uses
GENOME [18] as the default sequence generator, which
efficiently generates data using the coalescent model.
SeqSIMLA also accepts a population of sequences gen-
erated by other sequence generators. SeqSIMLA can
simulate multiple causal variants in regions on different
chromosomes, where the recombination rates between
regions are based on the rates estimated from the Hap
Map project [11] or a user-specified fixed rate. We com-
pared the features between SeqSIMLA and SimRare and
used simulations to demonstrate that SeqSIMLA can
generate data in a reasonable time frame.
Implementation
Sequence generation
GENOME is used as the default tool to simulate a popula-
tion of sequences based on the coalescent model. Alterna-
tively, as other sequence simulators can have their own
unique features, SeqSIMLA also accepts a population of
sequences generated by other programs. GENOME either
accepts different recombination rates among chromo-
somal blocks or assumes a fixed rate across the genome.
There is no recombination within each of the chromo-
somal blocks. To simulate block structures similar to real
populations, we downloaded the recombination hotspots
across the genome from the HapMap project [11], with
the highest recombination rate in each hotspot region
used as the recombination rate for the center of the
hotspot. Crossovers during meiosis are simulated based
on the recombination rates for the centers of hotspots. Al-
ternatively, the user can assume that the recombination
rates are uniform across the chromosomes, which is the
default setting in GENOME.
Disease models
We do not have restrictions on the number of disease
loci to be simulated. A logistic function as follows is
used to calculate the penetrance:
P Affected XÞ ¼ exp αþ BXð Þ= 1þ exp αþ BXð Þð Þjð
where X = (G1,G2,…,Gn) is a vector of genotype coding
for n disease variants, B= (β1, β2,…, βn) is a vector of the
conditional log of odds ratios for the associated geno-
types, and α determines the disease prevalence K. The
parameter α is ln (f0/(1 − f0)), which is the log odds ofthe penetrance for X with no mutant alleles. The odds
ratio eβi represents the increased odds for the disease for
an additional mutant allele at variant i [19]. For the
prevalence model (Model 1), the disease prevalence K is
specified by the user. We iteratively search for α in the
range between −20 and 20 and calculate disease preva-
lence Ki based on αi in iteration i. The value αi is se-
lected for α if |Ki − K| < ε, where ε is small (e.g., 0.001).
Alternatively, the user can specify f0 directly, and uses
the population attributable risk (PAR) to determine the
GRRs for the disease loci (the PAR model or Model 2).
The logistic function can be represented by the function




 ¼ f 0∏ni¼1GRRkið Þ.






GRRi ¼ PARi1−PARið Þ  Ri þ 1;
where f0 is the baseline penetrance specified by the
user, GRRi is the GRR for the genotype at marker i, PARi
is the population attributable risk, and Ri is the risk al-
lele frequency for marker i. The sum of PARi for the dis-
ease loci is equal to the overall PAR specified by the
user. The parameter k is coded as the number of mutant
allele counts (0, 1, 2) for an additive model, the pres-
ence/absence of an mutant allele (2/0) for a dominant
model, and the presence/absence of a homozygous mu-
tant genotype (2/0) for a recessive model. The model
can assume that rarer variants have higher GRR values,
given all causal variants contribute equally to the total
PAR. SeqSIMLA can also randomly generate a PAR for
each of the disease loci, while keeping the overall PAR
fixed. Alternatively, the user can specify a fixed GRR
across all disease loci.
The user can simulate dominant, recessive, or additive
models for the disease loci under Models 1 and 2. The
disease model is determined by the genotype coding in
X for Model 1 and by the parameter k for Model 2. For
Model 1, the user can specify whether a variant has a
risk or protective effect using the parameters in B. For
Model 2, the GRR for variant i with a protective effect is
the inverse of GRRi. The user can also specify the pro-
portion of risk variants in all variants with effects.Quantitative trait
We also do not have restrictions on the number of
quantitative trait loci (QTL). The user needs to specify
the total phenotypic variance VP and the proportion of
variance explained by each of the QTL. Assuming that
the proportion of variance explained by QTL j is fj and
the allele frequencies for QTL j are pj and qj, the
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ant, and recessive models as follows [20]:

















where VPj ¼ VPf j.
Assume QTL j has two alleles A1 and A2, where A1 is
the minor allele responsible for the larger value in the
trait. For a set of M QTL, the phenotypic value Y is a
random variable defined as:
Y ¼ μþ ∑Mj¼1ð ÞGj þ P þ E;
where μ is the general mean specified by the user, Gj
follows a normal distribution with mean μj and variance
VPj, P follows a normal distribution with mean 0 and
variance Vpoly specified by the user, and E follows a
normal distribution with mean 0 and variance
VP−∑Mj¼1VPj−Vpoly
 
. P and E model the polygenic and
environmental components, respectively. The mean μj
for Gj is defined as:
μj ¼
aj; 0;−aj for genotypes A1A1;A1A2;A2A2
under the additive model
aj; aj;−aj for genotypes A1A1;A1A2;A2A2
under the dominant model
aj;−aj;−aj for genotypes A1A1;A1A2;A2A2




SeqSIMLA can simulate two data types – three-generation
family data with 12 members and unrelated cases and con-
trols. The structure for each family is shown in Figure 1.
We assume random mating in a population of haplotypes
generated by GENOME to simulate family data. For the
disease models, a family is ascertained if there is a user-
specified number of affected siblings (e.g., 1–3) in the third
generation. To generate case–control data, we simulateFigure 1 Family structure simulated in SeqSIMLA.cases by randomly selecting unrelated affected individuals
and simulate controls by randomly selecting unrelated un-
affected individuals in the third generations of unrelated
families. For the quantitative trait model, the user can de-
cide whether the families will be ascertained based on affec-
tion status in family members, which is the same procedure
as in the disease models, or randomly from the population.
Efficiency improvements
SeqSIMLA determines that an individual is affected by
comparing the probability calculated from the pene-
trance function given the person’s genotypes to a ran-
dom number. This process can be inefficient for a rare
disease with low penetrance. We implemented a similar
strategy as in Edwards et al. [21] to efficiently simulate
unrelated cases. We first simulated a small set of cases
(e.g. 100 cases) using the penetrance function in Model
1 or 2. The conditional probability P(X|Affected) can be
calculated based on the set of cases, where X is a
multilocus genotype observed at the disease variants in
the set of cases. Then a multilocus genotype at the dis-
ease variants for a case is simulated based on the condi-
tional distribution, and two sequence haplotypes, which
are consistent with the multilocus genotype, are ran-
domly selected from the population of sequences. The
advantage of this method is that the run time is not af-
fected by the disease prevalence. However, the condi-
tional probability is subject to sampling error as it is
estimated in a small set of samples.
As generating each of the families, unrelated cases, and
unrelated controls is an independent process, the proce-
dures can be parallelized with threads on a multi-core
computer. We used Java Thread to parallelize the code.
Each thread generates about the same amount of families,
cases, and controls. We used simulations to evaluate the
performance of SeqSIMLA running with threads.
Results and discussion
SeqSIMLA is implemented in Java, which is portable on
different operating systems, including Linux and Win-
dows. The parameters required for SeqSIMLA can be spe-
cified in the command line. Alternatively, the user can
specify the parameters using a control file so that they can
be saved and reused. SeqSIMLA writes the variant data in
standard PLINK file format (map and ped files) [22],
which has been widely adopted in genetic analysis. Map
distance between two variants is calculated by Haldane’s
mapping function [23]. An additional phenotype file with
quantitative trait values, which is also in the same format
as the PLINK phenotype file, is generated if the user
chooses to simulate a quantitative trait.
We evaluated the performance of SeqSIMLA for gen-
erating datasets. We used the parameters provided in
the best-fitting population-genetics model [24], which
Chung and Shih BMC Bioinformatics 2013, 14:199 Page 4 of 6
http://www.biomedcentral.com/1471-2105/14/199includes estimates of ancestral population sizes, duration
of population expansion, migration rates, recombination
rates, final population sizes, and gene conversion rate, to
simulate a population of sequences with an allele fre-
quency spectrum similar to the European population in
GENOME. We simulated 1 block and 50 adjacent blocks
on chromosome 1, based on the recombination rates from
the HapMap project. As more than 30 functional variants
in coding regions can be identified in resequencing studies
for complex diseases [25,26], we simulated 30 disease loci
with minor allele frequencies less than 0.01 using Model
2. The overall PAR was set as 0.1. The baseline penetrance
f0 was set as 0.1, 0.01, and 0.001, reflecting prevalence of
different complex diseases. We also simulated two differ-
ent types of study samples: 500 families with at least one
affected sib, and 1000 cases and 1000 controls. The aver-
age time (over 100 replicates) spent on generating a
dataset was shown in Table 1. The simulations were
performed on a Linux server with Intel Xeon 2.4 GHz
CPUs (24 cores) and 96 GB of memory. As shown in
Table 1, SeqSIMLA can generate a dataset in a 1 block re-
gion with 1,177 SNPs in 8 seconds with 12 threads. Even
with a rare disease (prevalence 0.0014), SeqSIMLA with
threads can generate a dataset in a larger region (50 blocks
with 55,681 SNPs) in 5 minutes.
We performed linkage and rare-variant association
analysis on the data simulated by SeqSIMLA to verify
that SeqSIMLA is properly implemented. For linkage
analysis, 300 families with at least two affected siblingsTable 1 Run time of SeqSIMLA for generating family and
case–control data
1 Block 50 Blocks
(1,177 SNPs) (55,681 SNPs)
Prevalence1 0.11 0.012 0.0014 0.11 0.012 0.0014
Family2 4.88 s 6.09 s 16.6 s 3.85 m 4.06 m 7.58 m
(94%)7 (76%) (30%) (82%)8 (76%) (46%)
Family (T)3 4.58 s 5.33 s 7.52 s 3.35 m 3.45 m 4.51 m
(98%) (91%) (57%) (87%) (84%) (67%)
Case-control4 3.17 s 4.86 s 26.35 s 3.10 m 3.75 m 11.01 m
(64%) (33%) (6%) (34%) (29%) (11%)
Case–control (T)5 2.02 s 2.57 s 7.56 s 1.96 m 2.76 m 3.68 m
(88%) (74%) (20%) (34%) (37%) (22%)
Case–control (F)6 2.42 s 2.44 s 2.27 s 1.95 m 1.87 m 1.87 m
(91%) (91%) (92%) (58%) (58%) (58%)
1The estimated prevalence based on 10,000 prospective cohorts generated
under Model 2.
2500 families generated with 1 thread.
3500 families generated with 12 threads.
41000 cases and 1000 controls generated with 1 thread.
51000 cases and 1000 controls generated with 12 threads.
61000 cases and 1000 controls generated with the conditional probability of
multilocus genotypes given the disease status.
7Run time (seconds) and the percentage of run time spent on I/O.
8Run time (minutes) and the percentage of run time spent on I/O.were simulated. We simulated two regions (REGION1
and REGION2) on the same chromosome, where the re-
combination fraction between the two regions was 0.2. We
simulated 5 disease loci using Model 1 with MAF between
0.05 and 0.15 in REGION1, which has 374 variants. The
disease prevalence was 0.1. All disease loci were assumed
to have an effect size of 1.5, which was commonly observed
in GWAS studies [27]. REGION2 has 375 variants. For as-
sociation analysis, we simulated 1000 cases and 1000 con-
trols. We also simulated two regions (REGION3 and
REGION4) on the same chromosome, where the recom-
bination fraction between the two regions was 1. We simu-
lated 30 disease loci using Model 2 with MAF < 0.01 in
REGION3, which has 329 variants. The baseline pene-
trance f0 and the population attributable risk (PAR) were
specified as 0.1. REGION4 has 355 variants. A total of
1000 replicates of family and case–control data were simu-
lated for linkage and association analysis, respectively.
MERLIN [28] was used to perform linkage analysis (with
the --pairs option); and the Sequence Kernel Association
Test (SKAT) [29] implemented in the SKAT R package
was used to perform association analysis. Table 2 shows
the results of type I error rates and power calculated for
the null and alternative models, respectively. As shown in
Table 2, both MERLIN and SKAT have power for RE-
GION1 and REGION3, where the disease loci are located.
MERLIN also has power for REGION2, which is linked to
REGION1. SKAT has the correct type I error rate for RE-
GION4, which is not linked to the disease loci.
Two penetrance functions, Models 1 and 2, are used to
determine disease status in SeqSIMLA. Model 1, which is
based on the logistic function and has been used exten-
sively in many simulation studies [19,30,31], allows the
user to determine the conditional odds ratio for each of
the disease variants and the disease prevalence. Therefore,
the user can simulate disease models based on estimated
odds ratios of candidate variants from previous association
studies and estimated disease prevalence from a preva-
lence study. Model 2, which is based on the population at-
tributable risk, has the advantage of controlling the overall
PAR for a group of disease variants. The model can as-
sume that rarer disease variants have higher GRRs, given
that all of the variants have the same PAR [8]. The model







1The proportion of tests being rejected at the 0.05 significance level over
1000 replicates.
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simulate a large number of rare disease variants with
different odds ratios, while keeping the overall PAR in a
specified value.
Both SeqSIMLA and SimRare are able to generate se-
quence data for independent samples, but with some dif-
ferent underlying settings. SimRare uses the forward-time
simulation program srv implemented in the SimuPOP en-
vironment to generate sequence data. The srv program
provides multi-locus selection models with random fitness
effects, which are ideal for simulating multiple rare vari-
ants under selection. The default sequence generator,
GENOME, in SeqSIMLA is a backward-time simulator.
Similar to the limitation in other backward-time simula-
tors, selection is not modeled in GENOME [32]. However,
the backward-time simulators are generally faster than the
forward-time simulators. For simulating disease status,
both SeqSIMLA and SimRare allow the user to specify the
odds ratios or population attributable risk for disease vari-
ants, the proportion of protective variants, the mode of in-
heritance, and the disease prevalence. For simulating
quantitative trait values, SeqSIMLA allows the user to spe-
cify the total phenotypic variance, the proportion of vari-
ance explained by each of the causal variants, and the
mean of the trait values, while SimRare allows the user to
specify the deviations from the mean.
Table 3 shows the comparisons of features between
SeqSIMLA and SimRare. Both tools provide multiple
disease and quantitative trait models with flexible par-
ameter settings. However, SeqSIMLA has two major ad-
vantages over SimRare. First, SeqSIMLA can simulate
three-generation families in addition to case–control
data, while SimRare simulates only case–control sam-
ples. Therefore, SeqSIMLA will be very useful for study-
ing the statistical properties for family-based design.
Second, SeqSIMLA is able to simulate different recom-
bination rates between chromosomal blocks, while
SimRare assumes a fixed recombination rate. This fea-
ture in SeqSIMLA will enable the user to simulate differ-
ent linkage disequilibrium (LD) structures among
chromosomal blocks. On the other hand, SimRare has
some unique properties that can be potentiallyTable 3 Comparisons of features between SeqSIMLA and SIM
Feature SeqSIMLA
Language C++/Java
Sequence simulator GENOME (default) or a sequence poo
Simulated region Multiple genes on multiple chromoso
Simulated data type Families/unrelated cases and controls
Recombination rate Variable/Fixed
Number of disease/trait models 3
User interface Command lineimplemented in SeqSIMLA. For example, the power com-
parison module allows the user to perform a power study
based on existing and newly developed statistical tests,
and the graphical user interface provides a user friendly
interface for parameter settings.Conclusions
We implemented two disease models in SeqSIMLA, in
which the user can flexibly specify the number of disease
loci, effect sizes or PAR, disease prevalence, and risk or
protective loci. We also implemented a quantitative trait
model, in which the user can specify the number of QTL,
proportions of variance explained by the QTL, and genetic
models. We compiled recombination rates from the
HapMap project, so that genomic structures similar to real
data can be simulated. Future development of SeqSIMLA
includes more flexibility in simulating family structures,
such as twins or multi-generation families. SeqSIMLA can
be used as a complementary tool to SimRare. If the user
would like to perform a power study based on case–con-
trol design for new and existing statistical methods,
SimRare is ideal. If the user would like to perform a power
study for family-based design, or to simulate causal vari-
ants in multiple genes with different LD patterns among
genes, SeqSIMLA is more suitable. In summary, as statis-
tical methods for rare variant association analysis are de-
veloping rapidly, SeqSIMLA will be useful for evaluating
statistical properties for the new methods based on case–
control or family designs. SeqSIMLA will also be useful
for power studies when planning association studies based
on NGS.Availability and requirements
Project name: SeqSIMLA
Project home page: http://seqsimla.sourceforge.net
Operating system(s): Unix, Linux, Windows
Programming language: Java
Other requirements: Java JDK 7
License: GNU GPL
Any restrictions to use by non-academics: NoneRARE
SimRare
Python/C++
l generated by a simulator srv in SimuPOP
mes A gene or multiple independent genes
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